Relationship Between Metabolic DysfunctionAssociated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers

被引:0
|
作者
Rossi, Felipe A. Munoz [1 ]
Agudelo, Juanita Salazar [2 ]
Castro, Nestor Israel Quinapanta [3 ]
Mosquera, Sofia Z. [2 ]
Fajardo, Maria Clara Mejia [4 ]
Lopez, Edgar Dario Mosquera [5 ]
Olarte, Jonathan Dany Espitia [1 ]
Medina, Maria Andrea Figueroa [6 ]
Simancas, Edwin Zuniga [7 ]
Osuna, Luis Fernando Saldarriaga [8 ]
机构
[1] Univ Nacl Colombia, Internal Med, Bogota, Colombia
[2] CES Clin, Emergency Med, Medellin, Colombia
[3] Reg Autonomous Univ Andes, Res & Biostat, Ambato, Ecuador
[4] Cooperat Univ Colombia, Gen Med, Medellin, Colombia
[5] Univ Cent Ecuador, Gen Med, Quito, Ecuador
[6] Libre Univ Colombia, Gen Med, Barranquilla, Colombia
[7] Sinu Univ, Cardiovasc & Metab Ctr, Gen Clin Caribbean, Blas Lezo Clin,Internal Med, Cartagena, Colombia
[8] Univ Nacl Colombia, Bogota, Colombia
关键词
non-alcoholic fatty liver disease; gamma glutamyl transferase (ggt); nash and steatosis; high-density lipoproteins (hdl-c); lipoprotein (a); INSULIN-RESISTANCE; RISK; STEATOHEPATITIS; EPIDEMIOLOGY; ASSOCIATION;
D O I
10.7759/cureus.63019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Metabolic dysfunction -associated steatotic liver disease (MASLD) primarily affects the adult population and is closely related to obesity. The most severe form of MASLD, metabolic dysfunctionassociated steatohepatitis (MASH), can progress to liver fibrosis. While lipoprotein(a) (Lp(a)) is known to be associated with cardiovascular disease, its relationship with MASLD remains unclear. This study aims to determine the prevalence of MASLD in ambulatory patients and to explore the association between Lp(a) levels and advanced liver damage. Methods: This retrospective cross-sectional study included 130 patients older than 18 years seen in a healthcare center in Medellin, Colombia, between April 2023 and May 2024. Sociodemographic, clinical, and specific biomarker data were collected. Patients with cirrhosis, previous liver disease, frequent alcohol consumption, cancer, and other severe conditions were excluded. Continuous variables were analyzed using Student's t -tests or Mann -Whitney tests according to their distribution, and categorical variables were analyzed using contingency tables and chi-square tests. Results: Of the 130 patients, 57.9% (n=73) had MASLD, with a higher prevalence in patients with obesity (80%, n=32). Lp(a) levels were abnormally high in 43.1% (n=31) of patients; however, a weak but significant inverse correlation was found between Lp(a) levels and the Fibrosis -4 (FIB -4) score, which is used to assess the severity of liver fibrosis. Patients with MASLD had significantly lower high -density lipoprotein (HDL) and vitamin D levels, and higher levels of gamma-glutamyl transferase (GGT). Conclusions: This study highlights the significant prevalence of MASLD in outpatients and its relationship with various biomarkers, including Lp(a), HDL, vitamin D, and GGT. Although the findings suggest a possible utility of Lp(a) as a biomarker in MASLD, longitudinal studies are needed to confirm these associations and clarify their role in liver disease progression. The study's limitations include its cross-sectional nature and potential selection bias, indicating the need for further research to validate these results.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] ASSOCIATION OF BIOMARKERS WITH HEPATIC COLLAGEN QUANTIFICATION IN PATIENTS WITH METABOLIC DYSFUNCTION- ASSOCIATED STEATOTIC LIVER DISEASE ( MASLD)
    Tan, Daisong
    Koenig, Aaron
    Felix, Sean
    Estep, Michael
    Monge, Fanny
    Lam, Brian
    Racila, Andrei
    Stepanova, Maria
    Goodman, Zachary
    Younossi, Zobair
    HEPATOLOGY, 2024, 80 : S1535 - S1536
  • [42] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    HEPATOLOGY, 2023,
  • [43] Therapeutic management of metabolic dysfunction associated steatotic liver disease
    Zeng, Jing
    Fan, Jian-Gao
    Francque, Sven M.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024, 12 (02) : 177 - 186
  • [44] Oxidized high-density lipoprotein and low-density lipoprotein in adolescents with obesity and metabolic dysfunction-associated steatotic liver disease
    Bartlett, Alyssa M.
    Boone, Ali M.
    Bays, Jordan A.
    Kim, Youngsil
    Palle, Sirish K.
    Short, Kevin R.
    PEDIATRIC OBESITY, 2025, 20 (02)
  • [45] Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Orfanidou, Myrsini
    Polyzos, Stergios A.
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [46] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [47] Metabolic dysfunction-associated steatotic liver disease in adults
    Huang, Daniel Q.
    Wong, Vincent W. S.
    Rinella, Mary E.
    Boursier, Jerome
    Lazarus, Jeffrey V.
    Yki-Jarvinen, Hannele
    Loomba, Rohit
    NATURE REVIEWS DISEASE PRIMERS, 2025, 11 (01):
  • [48] Metabolic dysfunction-associated steatotic liver disease in children
    Goyal, Nidhi P.
    Xanthakos, Stavra
    Schwimmer, Jeffrey B.
    GUT, 2025,
  • [49] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    MATURITAS, 2024, 186
  • [50] Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Stefan, Norbert
    Roden, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 : S290 - S296